Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 12/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.48 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705492 | 0.88 | HDAC1 (0.51) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL1705984 | 0.85 | HDAC1 (0.52) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL197036 | 0.83 | CYP17A1 (0.54) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL30059279 | 0.83 | CYP17A1 (0.54) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL26170484 | 0.82 | CYP17A1 (0.48) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL25214971 | 0.80 | CYP17A1 (0.46) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL1646305 | 0.79 | AAK1 (0.47) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL30091846 | 0.79 | HDAC1 (0.56) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL1708159 | 0.79 | HDAC1 (0.46) | HDAC2CYP17A1HDAC1KCNQ4KCNQ5 | |
| SCHEMBL14155932 | 0.78 | CYP17A1 (0.58) | CYP17A1WDR5ABCB1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8258316-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | HDAC2 5/4885CYP17A1 1381/4885HDAC1 1/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | HDAC2 5/4885CYP17A1 1381/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.